Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01177
|
|||||
| Drug Name |
Hydroxyurea
|
|||||
| Synonyms |
1-HYDROXYUREA; Biosupressin; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; DRG-0253; Droxia; Droxia (TM); Droxia (TN); H 8627; HYDREA (TN); HYDROXY-UREA; Hidrix; Hidroxicarbamida; Hidroxicarbamida [INN-Spanish]; Hydrea; Hydrea (TM); Hydrea, Biosupressin, Cytodrox, Hydroxyurea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamide (JAN/INN); Hydroxycarbamidum; Hydroxycarbamidum [INN-Latin]; Hydroxycarbamine; Hydroxyharnstoff; Hydroxyharnstoff [German]; Hydroxylurea; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); Hydura; Hydurea; Idrossicarbamide; Idrossicarbamide [DCIT]; Litaler; Litalir; Mylocel; N-(Aminocarbonyl) Hydroxyamine; N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; NHY; Onco-carbide; Oncocarbide; Oxyurea; S-phase/G-1 interface inhibitor; SK 22591; SQ 1089; SQ-1089; Siklos; Tetratogen: inhibits ribonucleoside diphosphate reductase
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Chronic myelogenous leukemia [ICD11:2A20.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
CH4N2O2
|
|||||
| Canonical SMILES |
C(=O)(N)NO
|
|||||
| InChI |
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
|
|||||
| InChIKey |
VSNHCAURESNICA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 127-07-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 76.055 | Topological Polar Surface Area | 75.4 | ||
| Heavy Atom Count | 5 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
-1.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11111283
,11120331
,11120819
,11121307
,11335731
,11360970
,11363803
,11366365
,11368927
,11371484
,11373522
,11377089
,11404371
,11407166
,11446788
,11461942
,11483983
,11487880
,11490278
,11491827
,11494723
,11538819
,12014598
,14747331
,17137218
,17405158
,24278474
,24879294
,26611777
,26679201
,26697171
,26747533
,26747534
,26747535
,26758911
,29222781
,30388908
,3135371
,32810068
,5137976
,601956
,7847407
,7849615
,7979551
,8136972
,8149381
,8152311
,842099
,90752
,9256
|
|||||
| ChEBI ID |
ChEBI:44423
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [2] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Hydroxyurea was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56. | |||||
| 3 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.